4572 Carna Biosciences
- 313
- -6-1.88%
Carna Biosciences News
Carna Biosciences: Notice of sponsorship provision to CLL Society (US)
Carna Biosciences: Notice of presentation at the American Society of Hematology (ASH) Annual Meeting on the BTK inhibitor docirbrutinib (AS-1763)
Carna Biosciences: Notice of determination of the International Drug Name (INN) for AS-1763
Carna Biosciences: Change report (exemption share certificates, etc.)
Carna Biosciences: Notice of commencement of BTK inhibitor AS-1763 phase 1b test dose expansion part administration
Carna Biosciences: Mass Ownership Report
Carna Biosciences: Share Transfer Report Relating to Third-Party Allocation (New Shares)
Carna Biosciences: Stock transfer report agreement relating to third party allotment (new shares)
Carna Biosciences: Notice regarding completion of payments relating to the issuance of new shares through third-party allotment
Carna Biosciences: Mass holding report (stock certificates subject to special cases, etc.)
Carna Biosciences: Supplementary explanatory materials on the issuance of new shares through third-party allotment
Carna Biosciences: Notice Concerning Issuance of New Shares through Third-Party Allocation
Carna Biosciences: Interim report
Carna Biosciences: Notice of decision to start BTK inhibitor AS-1763 phase 1b test dose expansion part
Carna Biosciences: Notice of patent assessment in Europe relating to a joint patent application with Gilead Sciences
Carna Biosciences: Confirmatory letter.
Carna Biosciences: Interim report - 22nd term (January 1, 2024 - December 31, 2024)
Carna Biosciences: Financial results presentation materials for the second quarter of the December 2024 period.
Carna Biosciences: 2nd quarter (interim period) financial statements as of December 2024 (Japanese standard) (consolidated)
Carna Biosciences: Report of transfer of new shares for third-party allotment.
Analysis
Price Target
No Data
No Data